Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Inclusion Criteria:

- A confirmed virological diagnosis of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection (by reverse-transcription polymerase chain reaction (RT-PCR)).

- Hospitalized (or in the Emergency Department awaiting a bed after hospitalization)

- Respiratory compromise as defined by requirement of oxygen supplementation to maintain
oxygen saturation ≥ 93% but not requiring mechanical ventilation

- Abnormal chest X-ray consistent with COVID-19 and not indicating other serious medical
condition that would serve as an exclusionary criteria

- Women and men must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

- Women who are breastfeeding

- Recent acute infection defined as:

i) Any acute infection within 60 days prior to randomization that required
hospitalization or treatment with parenteral antibiotics (not COVID-19 related) ii)
Any acute infection within 30 days prior to randomization that required oral
antimicrobial or antiviral therapy

- History of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis,
osteomyelitis, bronchiectasis)

- Prior exposure to BMS-188667 (abatacept)

Other protocol-defined inclusion/exclusion criteria apply